The Management of Neoplastic Disorders of Haematopoiesis in Children With Down's Syndrome

Br J Haematol. 2000 Sep;110(3):512-24. doi: 10.1046/j.1365-2141.2000.02027.x.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Asparaginase / administration & dosage
  • Child
  • Child, Preschool
  • Cytarabine / therapeutic use
  • Daunorubicin / administration & dosage
  • Disease-Free Survival
  • Down Syndrome / complications*
  • Down Syndrome / genetics
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Infant
  • Infant, Newborn
  • Leukemia / complications*
  • Leukemia / genetics
  • Leukemia / therapy*
  • Leukemia, Myeloid / complications
  • Leukemia, Myeloid / therapy
  • Male
  • Maternal Age
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Prednisone / administration & dosage
  • Remission Induction
  • Vincristine / administration & dosage

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Vincristine
  • Asparaginase
  • Prednisone
  • Daunorubicin

Supplementary concepts

  • PVDA protocol